Jump to content

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis (Q48105762)

From Wikidata

scientific article

Language	Label	Description	Also known as
default for all languages	No label defined
English	Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

author name string

Gobbini MI

1

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Smith ME

2

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Richert ND

3

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Frank JA

4

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

McFarland HF

5

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

publication date

1 September 1999

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Journal of Neuroimmunology

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

99

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

1

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

142-149

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide in relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunologic Mechanisms and Therapy in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Side-effects of intravenous cyclophosphamide pulse therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

24-month follow-up of multiple sclerosis patients treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnetic resonance in monitoring the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide: Effect on Experimental Allergic Encephalomyelitis in Lewis Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimisation of cyclophosphamide therapy in systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recognition and Management of Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood-brain barrier and the penetration of cytostatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0165-5728(99)00039-9

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48105762&oldid=2184901475"